Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MECP2 | P51608 | 1/20 | 0.43 |
| ▸ | CIT | O14578 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053299 | 0.95 | BRAF (0.40) | MAPTSMN1; SMN2MAPK1TP53MECP2 | |
| SCHEMBL15053398 | 0.92 | CYP2D6 (0.50) | MAPTMAPK1CITKDM4EMEN1 | |
| SCHEMBL3702438 | 0.92 | SMN1; SMN2 (0.45) | MAPTSMN1; SMN2MAPK1TP53MECP2 | |
| Hydrochloric Acid SCHEMBL28814343 | 0.91 | MAPT (0.44) | MAPTSMN1; SMN2MAPK1TP53MECP2 | |
| SCHEMBL15052740 | 0.91 | RAB9A (0.41) | MAPK1KDM4EALDH1A1BRAFMET | |
| SCHEMBL15053289 | 0.90 | AURKA (0.44) | MAPTSMN1; SMN2CITKDM4EMEN1 | |
| SCHEMBL15053102 | 0.90 | KDR (0.44) | BRAFKDRMAPK14TNNI3KRAB9A | |
| SCHEMBL15052968 | 0.90 | MEN1 (0.46) | MAPTSMN1; SMN2MAPK1TP53KDM4E | |
| SCHEMBL15053686 | 0.89 | MAPT (0.41) | MAPTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL15053367 | 0.89 | MET (0.40) | MAPTSMN1; SMN2KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | claimed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | MAPT 1276/4885SMN1; SMN2 3318/4885MAPK1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.